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Cardiometabolic risk factors such as type 2 diabetes or dyslipi-
daemia have become an increasing problem in the developed
countries. Rimonabant 20 mg is a novel treatment in conjunc-
tion with diet and exercise for obese and overweight patients
with associated cardiometabolic risk factors such as type 2 dia-
betes or dyslipidaemia. In the double blinded RCT RIO-Europe
(n = 1508) and RIO-Diabetes (n = 1047), rimonabant was shown
to improve weight, waist circumference, HDL-cholesterol, TG,
HbA1c and other cardiometabolic risk factors in overweight and
obese patients with or without T2DM. The study inclusion cri-
teria correspond to Danish treatment guidelines. OBJECTIVE:
To analyse the cost-effectiveness of rimonabant as a supplement
to diet and exercise in a Danish setting. METHODS: A Markov
model (RAINBOW), evaluating scenarios of 2 and 10 years of
treatment in a Danish setting, was used to evaluate cost-effec-
tiveness based on the RIO-Europe and RIO-Diabetes study.
Modelled outcomes were cost per QALY and LYG. Danish cost
and epidemiological data were applied. RESULTS: Depending on
the treatment length (2 or 10 years) and whether the patients
were obese with or without diabetes, the cost per QALY gained
was between €11,182 and €13,164, while the cost per LYG was
between €13,734 and €39,004. These ratios are within the limits
which are normally considered to be cost-effective. CONCLU-
SIONS: Rimonabant in conjunction with diet and exercise can
be a in overweight or obese patients with dyslipidaemia or type
2 diabetes.
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OBJECTIVES: Abdominal obesity is a major risk factor for car-
diovascular disease (CVD), diabetes, and related mortality. Little
information is available on the economic burden of abdominal
obesity. Therefore, the objective of this study was to assess the
current medical resource use in patients with abdominal obesity
in Belgium. METHODS: Data on resource utilization was ret-
rospectively (1/8/2004–31/7/2005) collected by general practi-
tioners (GP) in patients aged ≥45 with abdominal obesity and
with either a history of CVD- or diabetes, or either >=2 CVD
risk factors (hypertension, dyslipidemia, impaired glucose toler-
ance). GPs were selected based on setting (urban-rural) and geo-
graphical region (north-south). Cost analysis was performed for
the whole sample, and for 2 subpopulations: patients with a
history of CVD or diabetes (64%) and patients without a CVD-
history or diabetes. Both costs related and not related to obesity
were included. The perspective of the health care payer was
taken. RESULTS: 403 patients were studied. Mean age was 61.2
(St.Err. 0.5), females represented 65.26% of the patients. The
overall cost per year for the entire sample was €1758 (St.Err.
€129) including all costs related and not related to obesity.
Excluding the costs not related to obesity the yearly cost was
€995 (St.Err. €90). For the group of patients with a history of
CVD or diabetes these costs were €2109 (St.Err. €182) and
€1252 (St.Err. €130) respectively. For the subgroup of patients
without a history of CVD nor diabetes these costs were €1099
(St.Err. €138) and €534 (St.Err. €82). CONCLUSIONS: This ret-
rospective chart review shows that patients with abdominal
obesity have a considerable cost, especially in the presence of
CVD or diabetes but also if multiple cardiovascular and/or meta-
bolic risk factors are present. Fifty-seven percent of the total cost
of care is related to the patient’s obesity.
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OBJECTIVES: In order to evaluate the costs of different health
states for patients with cardiometabolic risk, a study was per-
formed to operationalize these health states, to identify individ-
uals from a claims database and assign them to the health states.
METHODS: Claims data of a German sickness fund with 1.5
million beneﬁciaries were used for the years 2000 to 2004. Only
patients aged 18–80 years were included who were continuously
covered by the health insurance during this period. Health 
states were composed of different attributes (diabetes mellitus
with/without micro- or macrovascular complication, hyperten-
sion, hypercholesteremia, hypertriglyceridemia, coronary heart
disease, obesity), each of them being transposed into appropri-
ate ATC codes or ICD-10 codes (inpatient, outpatient, sick leave
diagnosis). Patients were selected from the database according to
their health state pattern. RESULTS: Out of n = 774,132 bene-
ﬁciaries (62% male), n = 736,653 (95%) could be assigned to
one of the deﬁned health states. Most of them (58%) were allo-
cated to the health state without any of the deﬁned attributes.
27% had 1 to 4 cardiometabolic risk factors, but no diabetes.
Four percent had no diabetes, but had already experienced car-
diovascular diseases such as myocardial infarction and/or stroke.
6% matched one of the diabetes related health states. CON-
CLUSION: Typical limitations of any analysis performed on the
basis of claims data should be borne in mind. These comprise
lack of diagnostic accuracy and incomplete knowledge of the
patients’ case histories and clinical measures for severity of
illness. Nonetheless, claims data provide useful information for
economic modelling, as they derive from a naturalistic setting
and allow an unbiased view on health care delivery and utiliza-
tion under real-life conditions. This can determine the authen-
ticity of economic models.
POB5
A MODELLED COST-EFFECTIVENESS EVALUATION OF
SIBUTRAMINE THERAPY IN A HIGH RISK OBESE
POPULATION
Walters N1, Makino K1, Hutchinson J1, Shorter N2, Swanson M2,
Schulz M2
1M-TAG, a unit of IMS, Chatswood, NSW, Australia, 2Abbott
Australasia, Botany, NSW, Australia
OBJECTIVES: Obesity is a major risk factor for type 2 diabetes,
cardiovascular disease and stroke. Moderate weight loss of
5–10% is proven to be beneﬁcial, but often difﬁcult to achieve
with diet/exercise alone. The addition of sibutramine can reduce
and maintain weight loss through increased satiety and enhanced
resting metabolic rate. This study reviews the safety, efﬁcacy 
and cost-effectiveness of sibutramine with diet/exercise in obese
patients. METHODS: A patient level analysis was conducted of
23 RCTs of sibutramine with diet/exercise compared with
diet/exercise alone. Dichotomous outcomes (proportion of
patients losing ≥5% body weight) and multivariate risk factor-
adjusted continuous means (BMI, SBP/DBP, HbA1c and lipids)
were calculated. Least squares regression models were developed
to determine the relationship between BMI change and cardio-
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vascular risk factors used in the economic model. A Markov
decision-analytic model using the Monte-Carlo simulation was
employed to examine cost-effectiveness. Hypothetical patients
were subject to risk of type 2 diabetes, CVD and stroke. Dia-
betic patients were at added risk of amputation, blindness 
and renal failure. Simulation of events was performed using 
the Framingham Heart Study and the UK Prospective Diabetes
Study. RESULTS: Signiﬁcant clinical beneﬁts were demonstrated
with sibutramine and diet/exercise compared with diet/exercise
alone: proportion of patients achieving ≥5% weight loss (51.6
vs 22.3% respectively; p < 0.0001), BMI (−1.65 [−1.97, −1.34]
kg/m2; p < 0.0005), absolute weight (−3.84 [−5.18, −2.49] kg; p
< 0.0005), HDL (4.07 [1.50, 6.65] mmol/L; p = 0.002) and
triglycerides (−12.17 [−21.82, −2.52]; p = 0.013). Small increases
in blood pressure (1–3 mmHg) and heart rate (4–5 beats/minute)
were observed. Sibutramine was a cost-effective addition 
to diet/exercise (approximately AUD$40,000 per additional
QALY). Sensitivity analyses demonstrated the model to be
robust. CONCLUSIONS: Sibutramine is a safe, effective, and
cost-effective intervention in the prevention of obesity-related
complications through weight loss and weight maintenance.
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For observational studies derived from Internet based cohorts,
the representativeness of demographic, behavioral and health
characteristics of subjects is not well-established in European
countries. OBJECTIVES: To compare distributions of self-
reported characteristics of subjects recruited via Internet in
Germany & UK to a national representative sample in each
country. METHODS: PROCEED is a multinational observa-
tional cohort of overweight & obese subjects (body mass index
>25 kg/m2) recruited through an existing Internet panel in
Germany & the UK in 2005. Eligibility criteria were: age 35–75;
not pregnant; willing to lose weight in the next year and weight
< 180 kg. Recruitment was stratiﬁed to balance gender and over-
weight and obese categories. Baseline demographics and selected
health and behavior characteristics of the PROCEED cohort
were compared with estimates from a relevant subset (same age,
BMI and not pregnant) of two National Surveys (1998 GNHIS
and 2003 HSE). PROCEED data were standardized for gender
and BMI category in each of the national surveys. RESULTS:
PROCEED subjects in Germany (n = 203) and the UK (n = 216)
presented similar characteristics to each national survey popula-
tion in terms of level of alcohol consumption, and prevalence 
of hypertension, high cholesterol and diabetes. More PROCEED
subjects reported having college or higher education (22% versus
12% in Germany; 31% versus 15% in the UK). PROCEED 
subjects were also more likely to be single. The German
PROCEED cohort had a higher proportion of current smokers
compared to GNHIS data (48% versus 24%) while the UK
PROCEED cohort was very similar to HSE data. CONCLU-
SIONS: Despite few differences in education level, marital and
smoking status, most demographic and health characteristics
were similar between the Internet cohort of overweight/obese
subjects and the German and UK national surveys.The internet
seems to be an appropriate tool for recruiting subjects in obser-
vational studies.
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OBJECTIVES: The objective was to examine the relationship
between changes in body weight and determine if there was causal
association with corresponding changes in health-related utility
measured by EQ5Dindex. METHODS: Data were extracted from
the Health Outcomes Data Repository (HODaR). Data from sub-
jects with multiple surveys were included. Analyses were con-
ducted to determine the relationship between changes in weight
and associated change in utility; overall and for different age, sex,
body mass index (BMI) and disease groups. RESULTS: The total
number of patients included was 8,286. The mean number of
completed questionnaires was 2.25. The mean time between ques-
tionnaires was 500 days (inter-quartile range [IQR], 1120). The
mean weight change was −0.027 kg (IQR = 5 kg). Weight did not
change in 19.8% of men and 18.3% of women. For men and
women, respectively, weight changed more than 3 kg in 35.3%
and 37.6%, more than 5 kg in 22.2% and 23.2% and more than
10 kg in 5.9% and 5.7%. An association between health utility
and weight gain could only be veriﬁed in high BMI groups (obese
class I–III; i.e. BMI > 30 kg/m2) with high weight gain (5 kg, 
10 kg). In these categories in men health utility decreased between
0.058 units (weight gain >5 kg, obese I) and 0.590 units (weight
gain >10 kg, obese I) in comparison to −0.006 (weight change up
to 5 kg, obese I) and −0.092 (weight change up to 5 kg, obese III)
for patients with lower weight change. In women these values
varied between 0.025 units (weight gain >5 kg, obese II) and 0.060
(weight gain >10 kg, obese II) and −0.001 (weight change up to
5 kg, obese II) and 0.017 (weight change up to 10 kg, obese I).
CONCLUSION: A negative relationship between weight gain and
health utility was veriﬁed. This relationship depended on the
initial weight and the magnitude of weight change.
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OBJECTIVES: Weight gain is a common side effect of many ther-
apies for type 2 diabetes (T2DM). This study reviews the medical
literature to summarize the consequences of weight gain on
health-related quality of life. METHODS: A review of the
medical literature, including MEDLINE, EMBASE, PsycINFO,
and abstracts from professional conferences, was conducted to
identify studies assessing the impact of body weight on patient
utility. Similarities and differences in study methodology and
results were evaluated. RESULTS: Seventeen papers presented
either: a) utility values by BMI or body weight or b) the change
in utility scores or QALYs based on unit changes in BMI or body
weight. Regardless of the patient population or methodology
used to elicit utility scores, all studies reviewed found as body
weight increased, patient utility decreased. Utility scores
obtained using standard gamble techniques were generally higher
than those using Time Trade Off or the EQ-5D. Most studies
evaluated utility scores stratiﬁed by body weight or BMI and
used regression analyses to attribute the difference in utility
scores to differences in weight while controlling for other factors.
Two studies used standard gamble methodology to evaluate the
change in utility scores by asking patients to evaluate the impact
of speciﬁc amounts of weight gain or loss. Studies generally
